Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
1 evidence topic · 3 sources
Summary
Zeleciment rostudirsen is being developed for individuals with DMD mutations amenable to exon 51 skipping. The proposed regimen is 20 mg/kg intravenously every four weeks, with doses expressed as the PMO component. DELIVER required stable background glucocorticoids for at least 12 weeks. The reported commercial launch remains conditional on approval; final commercial distribution and administration-site requirements are not established in this report.